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support the cost-effective use of NHS resources, but other factors regularly influ-
ence decision-making.
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ASSESSING THE QUALITY OF MANUFACTURERS’ SEARCHES IN NICE SINGLE
TECHNOLOGY APPRAISALS BY EVIDENCE REVIEW GROUPS
Wong R, Paisley S, Carroll C
The University of Sheffield, Sheffield, UK
OBJECTIVES: No guidelines exist in the approach that Evidence Review Groups
(ERGs) should take to appraise search methodologies in the manufacturer’s sub-
mission (MS) in single technology appraisals (STA). As a result, ERGs are left to
appraise searches using their own approach. This study investigates the limita-
tions of manufacturers’ search methodologies as critiqued by ERGs in published
STA reports. METHODS: Limitations from search critiques in 83 ERG reports pub-
lished in the NIHR website between 2006 and May 2011 were extracted. The limi-
tations were grouped into themes. Comparisons were made between limitations
reported in the clinical effectiveness versus cost-effectiveness searches. RESULTS:
Over 60 different limitations were identified and sorted in seven broad themes:
missing studies, search strategy, reporting, sources, limits, filters and translation.
The search strategy theme contained the most limitations. Missing studies were
frequently found by the ERG group in the clinical effectiveness searches. The omis-
sion of searches by manufacturers for unpublished and ongoing trials was fre-
quently reported by the ERG. By contrast, failure of the manufacturer to report
strategies was the most common limitation in the cost-effectiveness searches
which may explain the number of missing critiques in some ERG reports. Themes
with the most frequent limitations in both types of searches are search strategy,
reporting and source. CONCLUSIONS: Variations exist in the limitations reported
in both clinical and cost-effectiveness evidence searches in STAs. It is recom-
mended that separate checklists or one that incorporates both reporting and
search strategy appraisal be used to ensure that ERG groups and manufacturers are
aware of the range of limitations that might exist when appraising searches.
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PAYER INFORMATION REQUIREMENTS FOR RELATIVE EFFECTIVENESS
ASSESSMENT VARY ACROSS MARKETS AND CREATE DISCREPENCIES IN
PATIENT ACCESS TO MEDICINES
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OBJECTIVES: To 1) evaluate how relative effectiveness assessment (REA) is used
within the national pricing and reimbursement (P&R) processes in 8 developed and
emerging markets; 2) to understand payer REA requirements and preferences in
each of the markets studied; and 3) to analyse how the process impacts patient
access to medicines across geographies. METHODS: IHS studied national P&R pro-
cesses through primary and secondary research to establish how REA is leveraged
to rationalise reimbursement and control price levels. Over 30 key relative effec-
tiveness assessors and P&R decision makers were interviewed to understand the
level and type of relative effectiveness evidence they look for in practice, broken
down by public versus private sector, primary versus secondary-care segment, and
key therapeutic areas. This research was further supported by real-life REA case
studies across key therapeutic areas. RESULTS: The evaluation of the therapeutic
value of a medicine can result in P&R decision discrepancies across markets. These
coverage disparities notably reflect societal and methodological differences in the
way the available evidence is interpreted across markets. In terms of how thera-
peutic value is factored into P&R decisions, markets can be segmented into two
broad categories: 1) those that rely on economic evaluation to assess therapeutic
value, and 2) those that evaluate the added therapeutic value/improvement in
actual clinical benefit without considering associated costs. In terms of informa-
tion needs, payers wish to be in a position to evaluate how new medicines compare
with the standard of care in their specific health care setting and in their patient
population when making their P&R decisions. CONCLUSIONS: REA will increas-
ingly be used in future to rationalise finite health care resources and budgets. For
now there are two schools when it comes to the methodology and patient access to
medicines is more stringent in countries that undertake economic evaluation.
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EXPLORING THE ROLE OF THE COMMITTEE IN THE NICE APPRAISAL PROCESS:
HOW CONSISTENT ARE DECISIONS ACROSS COMMITTEES?
McCann E, Plested M
HERON, Luton, UK
OBJECTIVES: NICE technology appraisals are reviewed by one of four committees
(A to D). Given the standard submission template, the information submitted as
part of the appraisal process is the same across submissions. Therefore, commit-
tees may be expected to make similar decisions regarding the acceptance or rejec-
tion of submissions. This research explored whether there were differences in
acceptances or rejections between committees and which factors affected those
decisions. METHODS: Final appraisal determinations (FADs) from October 2009 to
May 2012 were identified and reviewed. The committee, decision, and reasons for
the decision were extracted from the FADs. Rates of acceptance or rejection were
compared across the four committees using Fisher’s exact test. The composition of
each committee and the considered therapy area were also assessed. RESULTS:
This research considered 53 submissions, from which 63 recommendations were
generated. Committee A made the highest proportion of positive recommenda-
tions (75%) and Committee D made the lowest proportion (50%). The background of
committee members was similar between Committees A and B, and between C and
D, but differed between those two sets. However, the number of acceptances or
rejections did not differ significantly by committee (p0.560). Limitations in clini-
cal evidence were cited as a reason for rejection more frequently than limitations
in economic evidence across all committees. The considered therapy areas differed
between committees though cancer was the most commonly-appraised area;
Committee C reviewed the highest proportion of cancer submissions. For this ther-
apy area, the rate of acceptance or rejection did not differ significantly by commit-
tee (p0.126). CONCLUSIONS: The likelihood of positive or negative recommenda-
tions did not appear to vary by the committee assessing the submission. Given the
reasons for negative recommendations and the proportion of academic committee
members, maximising the quality and rigour of submitted evidence is a rational
approach to the appraisal process.
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THE ROLE OF DECISION-ANALYTIC MODELING IN GERMAN HEALTH
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OBJECTIVES: Decision-analytic modeling has become a widespread method ap-
plied in Health Technology Assessments (HTA), but the extent to which modeling
is used differs widely among international HTA institutions. The German Agency
for Health Technology Assessment (DAHTA) states in its methodological guidelines
that model calculations can be carried out if necessary and feasible. However,
DAHTA does not provide any methodological guidance in this regard. Aim of this
study is to quantify the current role of decision-analytic modeling in DAHTA-re-
ports and to analyze the applied methods. METHODS: All 140 DAHTA-reports pub-
lished between 1998 and May 2011 were screened for the specific development of
new decision-analytic models. To assess the impact of these models on recom-
mendations, all relevant reports were reviewed with respect to the health eco-
nomic conclusion, modeling methods and further research needs. RESULTS: A
total of 90 DAHTA-reports incorporate an economic assessment. Of these, ten re-
ports develop a new specific decision-analytic model. About 30% of the reports
without a model come to a general economic conclusion but only one report gives
a clear recommendation without major limitations. About 20% of these reports
explicitly state that the development of a model for the German setting may have
helped to come to a clear conclusion. In contrast, all reports incorporating a model
give an economic recommendation – two of these with limitations. The identified
models differ with respect to the type of health economic evaluation (cost-effec-
tiveness, cost-utility), model type (decision tree, Markov model, Monte Carlo sim-
ulation), time horizon (two weeks – life long), discount rate (3%, 5%), perspective
(statutory health insurance, care provider, social), outcome parameters (generic,
disease specific) and sensitivity analyses (one-way, multi-way, probabilistic).
CONCLUSIONS: Incorporating decision-analytic models in German HTAs has the
potential to increase the number of health economic recommendations, but only a
fraction of reports developed a specific model so far.
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CALCULATED FORECAST FOR TECHNICAL OBSOLESCENCE IN COMPUTERISED
TOMOGRAPHY EQUIPMENT
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OBJECTIVES: To estimate the useful life of Computerised Tomography Equipment
(CT) METHODS: A main components analysis in this methodology has allowed for
a reduction in the number of variables on the survey-file in Computerised Tomog-
raphy technology and facilitates subsequent work without a significant loss of
information. The Log Binomial Regression Model has enabled probability calcula-
tions on answers (technology leap) to the different levels of stimuli (changes in
variables, temporary development, detection system, imaging resolution and
equipment power). Using a Discriminant analysis, the objective has been to esti-
mate, based on time, the chances of a technological leap occurring. RESULTS: The
18 evaluated technical parameters in Computerised Tomography Technology have
been grouped in three main components: Detection System which explains 72.4% of
the variance; Imaging Resolution which explaining 13.55% of the variance and Equip-
ment Power explaining 7.1% of the variance. Logistic regression allows us to approx-
imate the influence of each main component with the passing of time, the imple-
mentation of a technology leap, with its significant influence with positive signs of
temporary evolution (0.430), and with a negative sign for the main component the
detection system(3.974), image resolution (3.766) and equipment power
(2.460). For Determinant analysis, the explanatory variables used in the model are
the 3 components calculated. The prediction model obtains a lower percentage of
success than the Log Binomial, around 66.7%. The most important factor in influ-
encing the change of technology seems to be the image resolution followed by the
detection system and a negative sing for temporary evolution. CONCLUSIONS: The
results of the present project will enable advance knowledge of the expectations of
technological change in CT technology, allowing an advance in investment plan-
ning for this technology, for acquiring and installing this type of technology.
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COMPARING THE HUNGARIAN METHODOLOGICAL GUIDELINE FOR
CONDUCTING ECONOMIC EVALUATION OF HEALTH CARE INTERVENTION
WITH EUROPEAN GUIDELINES
Huszti Z, Nagy BZ
National Institute for Quality- and Organizational Development in Healthcare and Medicines,
Budapest, Hungary
OBJECTIVES: The Hungarian methodological guideline for conducting economic
evaluation of health care interventions was published in 2002 and the modified
version will be shortly published. The 10thanniversary of the Hungarian HTA
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guideline and the shortly coming updated version is an appropriate time to review
and compare it with other European guidelines in order to identify the main sim-
ilarities and differences in key features. METHODS: We chose 14 European guide-
lines and compared them based on the 32 key guideline features developed by
Hjelmgren et al. RESULTS: No relevant differences were found between the Hun-
garian and the European guidelines in tha major part (23) of the key features. The
Hungarian guideline represented nearly the same methodological aspects for ex-
ample in the choice of comparator, time horizon, discount rate and financial im-
pact analysis. We appraised relevant differences in the perspective of the PE stud-
ies, preferred analytical technic (CMA, CEA, CUA, CBA), systematic review of
evidences, costs to be included, preferred outcome measure and deliver utility. The
QALY is the preferred health outcome measure in cost utility studies almost in
every European countries, however only the English and Scottish guidelines re-
quire only EQ-5D profile to deliver utility. In the new version of the Hungarian
guideline the discount rate will be changed from 5% to 3,7%, the cost-effectiveness
threshold will be explicitly determined (twofold and threefold of GDP per capita)
and the direct comparisons will be preferred instead of indirect comparisons.
CONCLUSIONS:Generally we concluded that the Hungarian guideline published in
2002 and also the new modified version basicly require the same approach and
expectations as the European ones. Change in three main things (discount rate,
cost-effectivess threshold, direct comparison preference) makes our guidelines
more elaborated that could help the rational decision-making. The explicitly de-
termined cost-effectiveness threshold requires specification in the method of de-
livering utility in the future.
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OBJECTIVES: Swiss Health Technology Assessment (HTA) initiatives have been
fragmented, and official HTA processes by the Federal Office of Public Health
(Bundesamt fuer Gesundheit, BAG) have been limited to new technologies and
impaired by the absence of a clear-cut separation of assessment and appraisal.
METHODS: Therefore, santésuisse (the national association of sick funds) and In-
terpharma (representing the interests of the Swiss research-based pharmaceutical
industry) initiated “SwissHTA”, a transparent and inclusive project designed to
develop a national consensus how Switzerland might better use HTAs. The process
was led by a project team, with membership from santésuisse (and Helsana), In-
terpharma (and Roche), the Swiss federal government (BAG), the Swiss Medical
Association (FMH), and the Swiss Academy of Medical Sciences (SAMW). After
seven retreats of the project team and three workshops in the course of 12 months,
the team reached a consensus. RESULTS: The Swiss HTA consensus statement
emphasizes the need for a broad technology focus (covering both new and existing
ones by specific approaches following a common set of core principles) and recom-
mends opportunities for stakeholder involvement throughout the HTA processes.
Primary evaluation criteria should be determined by the social preferences of the
Swiss population, constrained by a prior normative commitment in line with con-
stitutional provisions and the principled, rights-based legal tradition of Switzer-
land. The full range of health-related benefits should be evaluated, and assessment
of clinical evidence should take into account the level of evidence that can reason-
ably be expected in a given context, rating the degree of confidence in outcomes in
relation to the relevance and the magnitude of the effects observed. Economic
viability should be evaluated based on budgetary impact and cost benefit ratios,
whereas the consensus rejects the idea of uniform cost per QALY benchmarks.
CONCLUSIONS: The Swiss HTA consensus combines a pragmatic approach with
well-defined evolutionary options.
PHP171
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OBJECTIVES: HTA has the increasing role in decision-making process in new EU
member states. Health care systems miscellaneousness causes differences in HTA
exploitation and its characteristics. Our objective was to make an overview of HTA
within these countries to show similarities and its differences. METHODS: Litera-
ture search was done on governmental and governmental like sites to find HTA
related Acts, regulation, guidelines or other relevant documents which describes
HTA country specific approach in new EU member states. First search was relevant
to presence of HTA. In those of them where HTA is defined in legislation we com-
pared several characteristics: model, role, type of HTA, role of pharmacoeconomic,
threshold, discounting factor, sensitivity analysis and differentiation of ap-
proaches between therapeutic and prophylactic approaches. RESULTS: Out of 12
new EU member states (accessed in May 2004 or later) 10 applies HTA, 8 as light
version, 2 as robust NICE like version. HTA has impactful position in 5 of them
(Poland, Slovenia, Slovakia, Estonia and Latvia). Only Poland applies full HTA ap-
proach. Rest of countries use narrow pharmacoeconomic approach. Threshold is
officially published in primary legislation in 2 countries (Poland, Slovakia). Dis-
counting factor varies between 3% and 5%. There was no difference recognized in
evaluation of either therapeutic or prophylactic approaches. CONCLUSIONS: HTA
form and role differ in new EU member states, but some similarities were identi-
fied. These similarities cannot presume any transferability of HTA decision, as it
depends on the other factors like health care system, composition of costs and
methods of its reimbursement by different bodies within relevant country. But
certain common areas for cooperation could be established based on that.
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CHALLENGES IN DEVELOPING A NEW SYSTEM FOR REGISTRATION OF PATIENT
REGISTRIES
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OBJECTIVES: Patient registries are an important tool for many types of clinical
research, including studies of comparative effectiveness, cost effectiveness, treat-
ment patterns, patient outcomes, and natural history of disease. Use of registries is
increasing, but there is no central database in the U.S. designed specifically to list
patient registries. A searchable public database that is designed to provide infor-
mation about patient registries would support research collaborations, reduce re-
dundancies, encourage the efficient use of resources, and improve transparency in
observational clinical research. The goal of this project, funded by the Agency for
Healthcare Research and Quality, is to design and develop a Registry of Patient
Registries (RoPR) system that meets the needs of a diverse set of stakeholders.
METHODS: Stakeholders from a broad range of organizations and with varying
levels of familiarity with patient registries were identified and invited to participate
in a series of remote and in-person meetings to gather and refine the RoPR system
requirements. Requirements were also revised through public comment and us-
ability and pilot testing. Over 320 individuals participated in RoPR design activities.
RESULTS: Stakeholders identified a range of challenges facing the RoPR system.
Challenges include improving understanding of the distinction between observa-
tional studies, patient registries, and other types of clinical research; determining
how to provide useful information to assess registry quality; ensuring that registry
listings are sufficiently complete; and motivating registry sponsors to list their
registries in a voluntary system. CONCLUSIONS: In response to stakeholder feed-
back, the RoPR was designed as an integrated system with ClinicalTrials.gov that
collects information on registry purpose, classification, objectives, data collected,
progress reports, and interest in collaboration and data sharing. Some challenges
identified through stakeholder discussions were addressed in the system design.
Other challenges must be addressed through education and collection of stake-
holder feedback following the RoPR launch in September 2012.
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DISENTANGLING THE RELATIONSHIP BETWEEN DISABILITY, SOCIOECONOMIC
STATUS AND SOCIAL CAPITAL IN CHILE: A POPULATION-BASED STUDY
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OBJECTIVES: Disability is a global public health priority strongly related to socio-
economic status (SES). Social capital (SC) is a complex construct and little is known
about how it relates to SES and disability in a middle-income country. This study’s
purpose was to explore this relationship in Chile. METHODS: Cross-sectional anal-
ysis of Chilean National Health Survey-2010 (n5037). Health outcome: Composite
index of disability (continuous variable, range 0-100). Dependent variables: a) SES
measures: household income per capita (tertiles), educational level (primary/sec-
ondary/higher), employment status (yes/no), and household assets index (tertiles).
b) SC dimensions: interpersonal trust (3 variables), financial/emotional support (2
variables) and social participation (2 variables). After factor analysis, s 2 factors
explained 60% variance (low uniqueness in all variables), with exception of social
participation which was assess separately. After orthogonal-varimax-rotation, 2
continuous aggregated variables were considered for analysis: trust and social sup-
port. Kaiser-Meyer-Olkin0.62; Cronbach alpha0.64 and 0.78 for trust and social
support, respectively. c) Demographic factors: age, sex, marital status, rural/urban
Weighted multiple linear regression models analyzed in R. Confounding and mul-
tiple interactions terms were explored. RESULTS: Mean of disability was 18.8pts. A
significant crude association between disability and SES was observed. All dimen-
sions of SC were significantly associated with disability (Trust: 7.6pts, Support:
10.7pts, Participation:2.0pts). Adjusted regressions showed SES reduced the
magnitude of its association to disability by 70% when dimensions of SC were
added to the model, but remained significant. Social participation lost statistical
significance in presence of SES. Multiplicative interaction terms were found be-
tween SC and education, providing additional higher chance to be disabled when
being poorly educated and having low trust and support. CONCLUSIONS: There is
a complex relationship between disability, SES and SC. Interactions between SES
and SC significantly modify the chance of being disabled and this needs further
consideration in the context of a middle-income country.
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PHYSICAL ACTIVITY MATTERS: THE ASSOCIATIONS BETWEEN BODY MASS
INDEX, PHYSICAL ACTIVITY AND HEALTH-REALTED QUALITY-OF-LIFE
TRAJECTORIES OVER 10 YEARS
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